{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:24:46Z","timestamp":1783297486378,"version":"3.54.6"},"reference-count":32,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008746","name":"National Cancer Center","doi-asserted-by":"publisher","award":["2P01CA225618-07"],"award-info":[{"award-number":["2P01CA225618-07"]}],"id":[{"id":"10.13039\/100008746","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.jtct.2025.02.024","type":"journal-article","created":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T12:19:13Z","timestamp":1741004353000},"page":"363.e1-363.e11","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Evaluation of Immunosuppression Levels and Risk of Graft-Versus-Host Disease in Allogeneic Blood or Marrow Transplantation With Post-Transplantation Cyclophosphamide"],"prefix":"10.1016","volume":"31","author":[{"given":"John J.","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haval","family":"Norman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5150-6982","authenticated-orcid":false,"given":"Jamie E.","family":"Ziggas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Bola\u00f1os-Meade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8341-5505","authenticated-orcid":false,"given":"Timothy J.","family":"Porter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jtct.2025.02.024_bib0001","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1586\/ehm.10.21","article-title":"Allogeneic hematopoietic cell transplantation: the state of the art","volume":"3","author":"Gyurkocza","year":"2010","journal-title":"Expert Rev Hematol"},{"issue":"1","key":"10.1016\/j.jtct.2025.02.024_bib0002","doi-asserted-by":"crossref","first-page":"25","DOI":"10.5966\/sctm.2012-0115","article-title":"Concise review: acute graft-versus-host disease: immunobiology, prevention, and treatment","volume":"2","author":"Sung","year":"2013","journal-title":"Stem Cells Transl Med"},{"issue":"20","key":"10.1016\/j.jtct.2025.02.024_bib0003","doi-asserted-by":"crossref","first-page":"4278","DOI":"10.1182\/bloodadvances.2021004941","article-title":"Nonrelapse mortality among patients diagnosed with chronic GVHD: an updated analysis from the chronic GVHD consortium","volume":"5","author":"DeFilipp","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2025.02.024_bib0004","unstructured":"Nash RA, Antin JH, Karanes C, et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors.2000."},{"issue":"8","key":"10.1016\/j.jtct.2025.02.024_bib0005","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1182\/blood-2014-04-567164","article-title":"Tacrolimus\/sirolimus vs tacrolimus\/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT","volume":"124","author":"Cutler","year":"2014","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.jtct.2025.02.024_bib0006","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","article-title":"HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide","volume":"14","author":"Luznik","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"10.1016\/j.jtct.2025.02.024_bib0007","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1016\/j.bbmt.2014.07.020","article-title":"Calcineurin inhibitor\u2013free graft-versus-host disease prophylaxis with post-transplantation cyclophosphamide and brief-course sirolimus following reduced-intensity peripheral blood stem cell transplantation","volume":"20","author":"Solomon","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"25","key":"10.1016\/j.jtct.2025.02.024_bib0008","doi-asserted-by":"crossref","first-page":"3817","DOI":"10.1182\/blood-2014-07-587477","article-title":"Single-agent GVHD prophylaxis with post-transplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS","volume":"124","author":"Kanakry","year":"2014","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.jtct.2025.02.024_bib0009","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1200\/JCO.2017.72.8428","article-title":"Mobilized peripheral blood stem cells versus unstimulated bone marrow as a graft source for T-cell\u2013replete haploidentical donor transplantation using post-transplant cyclophosphamide","volume":"35","author":"Bashey","year":"2017","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.1016\/j.jtct.2025.02.024_bib0010","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1056\/NEJMoa2215943","article-title":"Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis","volume":"388","author":"Bola\u00f1os-Meade","year":"2023","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jtct.2025.02.024_bib0011","doi-asserted-by":"crossref","first-page":"208.e1","DOI":"10.1016\/j.jtct.2022.12.017","article-title":"Three-year outcomes in recipients of mismatched unrelated bone marrow donor transplants using post-transplantation cyclophosphamide: follow-up from a national marrow donor program-sponsored prospective clinical trial","volume":"29","author":"Shaw","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"3","key":"10.1016\/j.jtct.2025.02.024_bib0012","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S1083-8791(98)50005-5","article-title":"Relationship of tacrolimus (FK506) whole blood concentrations and efficacy and safety after HLA-identical sibling bone marrow transplantation","volume":"4","author":"Wingard","year":"1998","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"10.1016\/j.jtct.2025.02.024_bib0013","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.bbmt.2003.12.305","article-title":"Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation","volume":"10","author":"Cutler","year":"2004","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"10.1016\/j.jtct.2025.02.024_bib0014","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/bmt.2015.323","article-title":"Higher tacrolimus concentrations early after transplant reduce the risk of acute GvHD in reduced-intensity allogeneic stem cell transplantation","volume":"51","author":"Ganetsky","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"10.1016\/j.jtct.2025.02.024_bib0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers13040613","article-title":"Effect of early post-transplantation tacrolimus concentration on the risk of acute graft-versus-host disease in allogenic stem cell transplantation","volume":"13","author":"Sharma","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jtct.2025.02.024_bib0016","unstructured":"Fuchs EJ, O'donnell P V, Eapen M, et al. Double unrelated umbilical cord blood vs HLA-haploidentical bone marrow transplantation: the BMT CTN 1101 trial on behalf of the blood and marrow transplant clinical trials network. http:\/\/ashpublications.org\/blood\/article-pdf\/137\/3\/420\/1798112\/bloodbld2020007535.pdf"},{"issue":"2","key":"10.1016\/j.jtct.2025.02.024_bib0017","article-title":"Sirolimus is an acceptable alternative to tacrolimus for graft-versus-host disease prophylaxis after haploidentical peripheral blood stem cell transplantation with post-transplant cyclophosphamide","volume":"30","author":"Elmariah","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"4","key":"10.1016\/j.jtct.2025.02.024_bib0018","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1182\/bloodadvances.2016002766","article-title":"Prospective study of nonmyeloablative, HLA-mismatched unrelated BMT with high-dose post-transplantation cyclophosphamide","volume":"1","author":"Kasamon","year":"2017","journal-title":"Blood Adv"},{"issue":"11","key":"10.1016\/j.jtct.2025.02.024_bib0019","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1016\/j.bbmt.2020.07.037","article-title":"Shortened-duration immunosuppressive therapy after nonmyeloablative, related HLA-Haploidentical or Unrelated Peripheral Blood Grafts and Post-Transplantation Cyclophosphamide","volume":"26","author":"DeZern","year":"2020","journal-title":"Biol Blood Marrow Transplan"},{"issue":"2","key":"10.1016\/j.jtct.2025.02.024_bib0020","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1177\/1078155215577809","article-title":"Factors associated with optimized tacrolimus dosing in hematopoietic stem cell transplantation","volume":"22","author":"Butts","year":"2016","journal-title":"J Oncol Pharm Pract"},{"issue":"1","key":"10.1016\/j.jtct.2025.02.024_bib0021","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.bbmt.2015.09.001","article-title":"International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the mount Sinai acute GVHD international consortium","volume":"22","author":"Harris","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.jtct.2025.02.024_bib0022","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. the 2014 diagnosis and staging working group report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Bio Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2025.02.024_bib0023","unstructured":"US Department of Health and Human Services. Common terminology criteria for adverse events, version 5.0. 2017. Accessed on August 31, 2023."},{"issue":"2","key":"10.1016\/j.jtct.2025.02.024_bib0024","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/s41409-021-01528-y","article-title":"Tacrolimus initial steady state level in post-transplant cyclophosphamide-based GvHD prophylaxis regimens","volume":"57","author":"Yao","year":"2022","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"10.1016\/j.jtct.2025.02.024_bib0025","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1016\/j.bbmt.2019.01.029","article-title":"Effect of graft-versus-host disease prophylaxis regimens on T and B cell reconstitution after allogeneic hematopoietic stem cell transplantation","volume":"25","author":"T\u00f6rl\u00e9n","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"25","key":"10.1016\/j.jtct.2025.02.024_bib0026","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1056\/NEJMoa2215943","article-title":"Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis","volume":"388","author":"Bola\u00f1os-Meade","year":"2023","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.jtct.2025.02.024_bib0027","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1016\/j.bbmt.2019.07.027","article-title":"Severe cytokine release syndrome after haploidentical peripheral blood stem cell transplantation","volume":"25","author":"Imus","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"10.1016\/j.jtct.2025.02.024_bib0028","doi-asserted-by":"crossref","first-page":"185.e1","DOI":"10.1016\/j.jtct.2022.01.003","article-title":"Outcomes following intolerance to tacrolimus\/sirolimus graft-versus-host disease prophylaxis for allogeneic hematopoietic cell transplantation","volume":"28","author":"Mirza","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"11","key":"10.1016\/j.jtct.2025.02.024_bib0029","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1080\/10428194.2022.2087067","article-title":"Post-transplant cyclophosphamide pharmacokinetics and haploidentical hematopoietic cell transplantation outcomes: an exploratory study","volume":"63","author":"Kasudhan","year":"2022","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1016\/j.jtct.2025.02.024_bib0030","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-022-00771-w","article-title":"Low-dose PTCy plus low-dose ATG as GVHD prophylaxis after UD-PBSCT for hematologic malignancies: a prospective, multicenter, randomized controlled trial","volume":"13","author":"Zu","year":"2023","journal-title":"Blood Cancer J"},{"issue":"4","key":"10.1016\/j.jtct.2025.02.024_bib0031","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/s41409-022-01908-y","article-title":"Reduced post-transplant cyclophosphamide doses in haploidentical hematopoietic cell transplantation for elderly patients with hematological malignancies","volume":"58","author":"Dul\u00e9ry","year":"2023","journal-title":"Bone Marrow Transplant"},{"issue":"Supplement 1","key":"10.1016\/j.jtct.2025.02.024_bib0032","doi-asserted-by":"crossref","first-page":"7591","DOI":"10.1182\/blood-2022-162581","article-title":"Access: a multi-center, phase II trial of HLA-mismatched unrelated donor hematopoietic cell transplantation with post-transplantation cyclophosphamide for patients with hematologic malignancies","volume":"140","author":"Al Malki","year":"2022","journal-title":"Blood"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636725010607?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636725010607?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T02:11:28Z","timestamp":1780279888000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636725010607"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S2666636725010607"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2025.02.024","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of Immunosuppression Levels and Risk of Graft-Versus-Host Disease in Allogeneic Blood or Marrow Transplantation With Post-Transplantation Cyclophosphamide","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2025.02.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}